erythropoiesis-stimulating agent

(redirected from Erythropoiesis stimulating agent)

erythropoiesis-stimulating agent

Abbreviation: ESA.
Any drug that binds to cellular receptors for erythropoietin and encourages red blood cell production by the bone marrow. Members of this class of drugs, which include epoietin and darbopoietin, are used to treat anemia, e.g., in patients with chronic kidney disease, cancer, or aplastic anemia. ESAs are used as an alternative to red blood cell transfusions. Potential side effects of treatment include high blood pressure and an increased risk of blood clots.
See also: agent
References in periodicals archive ?
An erythropoiesis stimulating agent or drug is a medicine which stimulates red blood cells protein erythropoiesis.
Peginesatide: A potential erythropoiesis stimulating agent for the treatment of anemia of chronic renal failure.
Thomas Byrne, was recently recognized as a co-inventor of the underlying technology of Amgen's blockbuster drug Aranesp (darbepoietin alpha), a erythropoiesis stimulating agent (US Patent No.
Tokyo, Japan, Apr 25, 2007 - (JCN) - Kirin Brewery announced that it received manufacturing and marketing approval for its long-acting erythropoiesis stimulating agent Darbepoetin Alfa, brand name NESP(R) Injection Syringe, on April 18, 2007.
Key Words: Anemia, erythropoiesis stimulating agent, chronic kidney disease.
Hematide, a peptide-based erythropoiesis stimulating agent (ESA) being developed by Affymax, is currently in clinical trials for the treatment of anemia associated with chronic kidney disease, cancer and other diseases.
Peginesatide is a synthetic PEGylated peptidic compound that binds to and stimulates the erythropoietin receptor and thus acts as an erythropoiesis stimulating agent (ESA).
Hematide[TM], a synthetic peptide-based erythropoiesis stimulating agent, maintains hemoglobin in hemodialysis patients previously treated with epoetin alfa (EPO).
If approved, peginesatide will be the first once-monthly erythropoiesis stimulating agent (ESA) available for the treatment of anemia associated with CKD patients on dialysis in the US, the firm said.
The market scenario will change following the launch of new disease modifying therapies such as ACEs inhibitor, antioxidant inflammation modulator, connective tissue growth factor (CTGF) Inhibitor, monocyte chemoattractant proteins (MCP) inhibitor, selective glycation inhibitor, transforming growth factor beta regulator, selective Endothelin-A Receptor (ETAR) antagonist, urotensin II receptor antagonist, IL-12 inhibitors and STAT-4 activator, Nox4 inhibitor, G protein-coupled receptors (GPCRs) antagonist, and erythropoiesis stimulating agent.
Hematide is a novel synthetic, PEGylated peptidic compound that binds to and activates the erythropoietin receptor and thus acts as an erythropoiesis stimulating agent (ESA).
Preliminary data from the Phase 2 randomized, active-controlled, open-label trial were presented in a poster entitled "Preliminary Analysis of Once-Monthly Hematide Efficacy and Safety in Hemodialysis Patients not on erythropoiesis stimulating agent (ESA) Treatment.